Navigation Links
Prednisone tablets less variable than marketed drugs
Date:4/1/2008

Rockville, Md., April 1, 2008 The U.S. Pharmacopeial (USP) Convention today announced results of a study comparing the dissolution variability of USP Prednisone Lot P Reference Standard tablets to two marketed drugs. Study results clearly show less variability in USP Prednisone Lot P tablets than in the marketed tablets. Dissolution testing of solid oral dosage forms plays a critical role in drug manufacturing because it indicates whether a drug will dissolve properly in the body. This in turn is an established criterion in quality assurance and regulation of manufactured drugs and dietary supplements.

In all analytical testing, including dissolution, the apparatus used must undergo installation, operation and performance qualification to ensure reliable results. These activities are detailed in various USP General Chapters, particularly Dissolution <711>. For dissolution testing, the performance verification test involves USP Prednisone Reference Standard tablets. The current study explored quality attributes of USP Lot P Prednisone Reference Standard tablets in comparison to two commercially available drugs that are marketed in tablet form.

The study was undertaken in response to assertions that the USP Prednisone Lot P Reference Standard tablets yielded highly variable results and led to unreliable dissolution test results. It compared the dissolution variability associated with selected commercial dosage forms to that of USP Lot P Prednisone Reference Standard tablets. The study was conducted according to metrological principles established by the International Organization for Standardization.

I am very pleased that the results of this testing showed significantly less variability in the USP Lot P Prednisone Reference Standard tablets than in the comparator tablets, said William Koch, Ph.D, chief reference materials officer for USP. USP Prednisone yielded an average variability of less than five percent, while comparators averaged about 13 percent. Established metrological principles were followed to ensure the tests objectivity, and it is clear that USP Prednisone Reference Standard tablets are not the cause of variation in dissolution test results, Dr. Koch continued. Manufacturers should be assured of the appropriate performance of the USP Prednisone tablets in dissolution testing.


'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Related biology news :

1. Variable light illuminates the distribution of picophytoplankton
2. Ant guts could pave the way for better drugs
3. Simplifying manufacture of drugs, plastics earns UH chemist top honor
4. Pharmaceutical breakthrough may make a range of drugs cheaper and more available
5. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
6. Physician-scientist urges improved drug regulation to ensure heart safety of non-heart drugs
7. Cheaper drugs now closer to realization with new DropArray technology
8. Club drugs inflict damage similar to traumatic brain injury
9. MIT: Remote-control nanoparticles deliver drugs directly into tumors
10. Market testing of dietary supplements and drugs underscores value of USPs public health programs
11. Scientists unveil structure of molecular target of many drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, ... could be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma ... read it now. , Biomarkers are components in the blood, tissue or ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
Breaking Biology Technology: